托珠单抗治疗大动脉炎不良反应的临床分析  

Clinical analysis of the efficacy and adverse reactions treating Takayasu’s arteritis with tocilizumab

作　　者：王莉莎[1] 徐锌 曲建昌[1] 梁艳玲[1] 赵红玉 王彤[1] WANG Lisha;XU Xin;QU Jianchang;LIANG Yanling;ZHAO Hongyu;WANG Tong(Department of Endocrine Rheumatology and Immunology,the 305 Hospital of PLA,Beijing 100039,China)

机构地区：[1]中国人民解放军第305医院内分泌风湿免疫科,北京100039

出　　处：《中国现代医生》2022年第23期95-98,共4页China Modern Doctor

摘　　要：目的 评价托珠单抗(tocilizumab,TCZ)治疗大动脉炎(Takayasu’s arteritis,TA)的临床疗效和安全性。方法 将2014年6月至2020年12月中国人民解放军第305医院内分泌风湿免疫科门诊治疗的13例难治性大动脉炎患者接给予托珠单抗治疗(4mg/kg,8mg/kg静脉输注),每月1次,随访3个月,评价TA患者的血红细胞沉降率、超敏C反应蛋白(hypersensitive C-reactive protein,hs-CRP)、血常规、谷丙转氨酶和不良反应,并对治疗过程中出现不良反应的3例患者随访3年,观察其临床疗效及不良反应情况。结果 13例TA患者临床症状均有不同程度的改善,3例患者出现不良反应。结论 托珠单抗治疗TA疗效显著,安全性较好,所引起的不良反应及其机制仍需进一步探讨。Objective To evaluate the clinical effects and safety of tocilizumab in the treatment of active Takayasu’s arteritis. Methods A total of 13 patients with refractory Takayasu’s arteritis who were received intravenous injection of tocilizumab(4 mg/kg, 8 mg/kg). The patients were followed up for 3 months. The indicators included erythrocyte sedimentation rate(ESR), hypersensitive C-reactive protein(hs-CRP), complete blood count, liver transaminase and adverse reactions were observed. During the treatment of TA with tocilizumab, the patients with adverse reactions were followed up for 3 years, and the different adverse reactions outcome were observed. Results The clinical symptoms of the 13 patients were improved in varying degrees, but there were 3 patients with different adverse reactions. Conclusion The therapeutic effect of tocilizumab on TA is remarkable. However, the adverse reactions and their mechanisms still need further attention and discussion.

关 键 词：大动脉炎 抗白介素-6受体抗体 不良反应 托珠单抗 

分 类 号：R743[医药卫生—神经病学与精神病学]